{
    "id": 32437,
    "fullName": "EPAS1 G323E",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EPAS1 G323E lies within the PAC domain of the Epas1 protein (UniProt.org). G323E has been demonstrated to confer resistance to HIF-2 inhibitors as a secondary resistance mutation (PMID: 31727677), but has not been biochemically characterized and therefore, its effect on Epas1 protein function is unknown (PubMed, Feb 2020).",
            "references": [
                {
                    "id": 285,
                    "pubMedId": null,
                    "title": null,
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 17770,
                    "pubMedId": 31727677,
                    "title": "HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31727677"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2034,
        "geneSymbol": "EPAS1",
        "terms": [
            "EPAS1",
            "bHLHe73",
            "ECYT4",
            "HIF2A",
            "HLF",
            "MOP2",
            "PASD2"
        ]
    },
    "variant": "G323E",
    "createDate": "02/05/2020",
    "updateDate": "02/05/2020",
    "referenceTranscriptCoordinates": {
        "id": 187523,
        "transcript": "NM_001430",
        "gDna": "chr2:g.46375771G>A",
        "cDna": "c.968G>A",
        "protein": "p.G323E",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 20246,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, a patient with clear cell renal cell carcinoma experienced stable disease while being treated with PT2385 for 87.1 weeks, but then progressed, and subsequent testing of the metastatic site identified EPAS1 G323E (PMID: 31727677).",
            "molecularProfile": {
                "id": 34970,
                "profileName": "EPAS1 G323E"
            },
            "therapy": {
                "id": 4146,
                "therapyName": "PT2385",
                "synonyms": null
            },
            "indication": {
                "id": 4467,
                "name": "clear cell renal cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17770,
                    "pubMedId": 31727677,
                    "title": "HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31727677"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 34970,
            "profileName": "EPAS1 G323E",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 187523,
            "transcript": "NM_001430",
            "gDna": "chr2:g.46375771G>A",
            "cDna": "c.968G>A",
            "protein": "p.G323E",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}